港股異動 | 多重利好加身 藥明生物(2269.HK)續漲逾3%
格隆匯8月18日丨昨日收漲4.71%的藥明生物(2269.HK)今日續漲,現報174.4港元,漲3.2%,暫成交4.7億港元,最新總市值2367億港元。藥明生物昨晚公佈中期業績稱,期內純利7.31億元(人民幣,下同),同比增長62.6%;經調整純利7.34億元,同比增長40.7%;每股盈利0.57元。該股亦獲摩通於8月11日增持約22.51萬股,涉資約3695.9萬港元。此外,藥明生物獲納入恆指成份股,變動將於9月7日起生效。大摩最新發研報指,本次“染藍”將提高藥明生物的企業知名度、投資者基礎、成交流動性和融資靈活性。作為恆指中權重最大的健康護理股,集團在股份轉換生效後料會吸引更多被動和主動資金流入,維持“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.